Neurodegeneration is the progressive loss of structure and/or function of neurons including death. Neurodegenerative diseases include; Alzheimer’s disease, Parkinson’s disease and Huntington’s disease.
The Stem Cells Transplant Institute in Costa Rica, recommends the use of human umbilical cord mesenchymal stem cells (hUC-MSC) for the treatment of Parkinson’s disease.
Transplantation of hUC-MSCs at sites of neuronal degeneration is a very promising approach for the treatment of different neurological diseases such as Parkinson`s Disease.
Treatment at the Stem Cells Transplant Institute could help improve the following symptoms of Parkinson´s disease:
Parkinson’s disease is the second most common type of neurogenerative disease, affecting over 10 million people, or approximately 1% of the population worldwide, over the age of 65.
Parkinson’s disease is characterized by a progressive loss of muscle control leading to bradykinesia (slow movement), rigidity, resting tremor and postural instability.
As symptoms worsen, it may be difficult to walk, talk, and perform simple tasks. Non-motor symptoms can include; anxiety, depression, psychosis, and dementia.1,2
The main pathological feature of Parkinson’s disease is the significant loss of dopamine neurons in the Substantia Nigra pars compacta.
The loss of the dopaminergic neurons is linked to the formation and accumulation of Lewy bodies. Dopamine is a chemical that acts as a messenger between brain cells. It plays a role in how we move, what we eat, and how we learn.
The substantia nigra, a tiny strip of tissue on both sides of the base of your brain produces dopamine. When the brain cells in the substantia nigra start to die, dopamine levels drop.
When the level of dopamine gets to low, you will begin to experience symptoms of Parkinson’s disease.
There is no cure for Parkinson’s disease and currently available therapeutic approaches only treat the symptoms of the disease
Frustration from limited treatment options has led to an increased focus on stem cell replacement therapy, treatment intending to provide long-lasting relief from symptoms of Parkinson’s disease.
Approximately 5% of patients diagnosed with Parkinson’s disease have an inherited genetic mutation.
Researchers are currently investigating the underlying cause of Parkinson’s disease in the other 95% of cases.
When dopamine was reintroduced into the central nervous system, symptoms were decreased or reversed. This means, if stem cells can be induced into becoming dopamine producing neurons and then transplanted in affected zones, they could replace impaired cells, improving function.1,2
Researchers have shown transplanting young brain cells derived from human fetuses into patients with Parkinson’s disease resulted in an improvement in disease related symptoms.
Animal studies have shown mesenchymal stem cells promote neuroprotection and neurodifferentiation, by modulating neural stem cells, neurons and glial cells and axonal growth.3-11 They have the ability to repair and regenerate neurons in the brain, reduce levels of free radicals, improve synaptic connection from damaged neurons and regulate inflammation.
It is not clear how mesenchymal stem cells perform these functions, but one theory is: injected stem cells are drawn to the injured area where they release trophic factors (molecules that support cell survival) that aid in repairing damaged cells. The trophic factors can suppress the local immune system, form new blood vessels, reduce levels of free radicals, stop the damage occurring to tissue, and increase the recruitment, retention, proliferations and differentiation of stem cells.2
Animal models have shown stem cell therapy has been shown to be safe and effective.
According to clinicaltrials.gov there are currently 23 trials being conducted worldwide evaluating stem cell therapy for Parkinson’s disease.
Two of the trials are evaluating specifically umbilical cord stem cells; there is one trial in China and one in Jordan.
Using their published data from a primate study, Chinese researchers have received approval to evaluate the safety and efficacy of human stem cells in patients with Parkinson’s Disease (A Phase I/II, Open-Label Study to Assess the Safety and Efficacy of Striatum Transplantation of Human Embryonic Stem Cells-derived Neural Precursor Cells in Patients With Parkinson’s Disease).
The study is a Phase I/II, open label, non-randomized clinical trial for 50 people diagnosed with Parkinson’s disease for more than 5 years. Results of the trial are expected in late 2020 or 2021.
The Stem Cells Transplant Institute recommends the use of hUC-MSCs for the treatment of Parkinson’s disease. For optimal results, we recommend a two-day treatment. Each day you will receive the following:
We still do not understand what specifically causes Parkinson’s disease.
Current traditional treatment options lose effectiveness over time and once the effectiveness is lost that therapy will no longer improve the worsening symptoms.
Clinical trials evaluating efficacy in humans have only recently started and the results will not be available for several years.
At this time stem cell therapy does not stop the underlying cause of Parkinson’s disease and patient may need more than one treatment due to a declining effect over time.
We use only umbilical cord stem cells that are derived exclusively from umbilical cord donations.
The umbilical cord stem cells from are collected after informed consent has been given by the parent, or parents, and only after the delivery of the baby.
The collection follows strict ethical protocols ensuring the stem cells are from safe, reliable sources using a non-invasive, simple and painless procedure.
Once collected, the cord blood is then screened for disease.
The stem cells are administered by intravenous and Intrathecal (spinal) injection
Costa Rica has one of the best healthcare systems in world and is ranked among the highest for medical tourism.
Using the most advanced technologies, the team of experts at The Stem Cells Transplant Institute believes in the potential of stem cell therapy for the treatment of neurodegenerative diseases.
We are committed to providing personalized service and the highest quality of care to every patient.